Overview Dividends

(FDMT) 4D Molecular Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001

Ophthalmology, Cystic-Fibrosis, Geographic-Atrophy, Alpha-1-Antitrypsin-Deficiency, Fabry-Disease

FDMT EPS (Earnings per Share)

EPS Growth (3Y CAGR): -33.62%
EPS Trend (3Y Correlation): -39.9%

FDMT Revenue

Revenue Growth (3Y CAGR): -61.55%
Revenue Trend (3Y Correlation): -39.1%

Risk via 10d forecast
Volatility	90.3%
Value at Risk 5%th	129%
Relative Tail Risk	-13.24%

Reward TTM
Sharpe Ratio	0.77
Alpha	21.73

Character TTM
Hurst Exponent	0.361
Beta	1.147
Beta Downside	1.420

Drawdowns 3y
Max DD	93.00%
Mean DD	51.30%
Median DD	50.02%

Description: FDMT 4D Molecular Therapeutics October 29, 2025

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a late-stage biotech focused on engineering adeno-associated virus (AAV) vectors through its proprietary Therapeutic Vector Evolution platform, operating labs in the Netherlands and the United States.

The company’s lead candidate, 4D-150, aims to treat retinal vascular diseases-including wet age-related macular degeneration (wAMD) and diabetic macular edema-by delivering a multi-year, intravitreal anti-VEGF expression system. The global anti-VEGF market is valued at roughly $10 billion and is projected to grow at a 6-7 % CAGR, making sustained-release gene-based approaches a potentially disruptive cost-controlling alternative.

Beyond 4D-150, the pipeline includes 4D-710 (early-stage cystic fibrosis), 4D-175 (preclinical geographic atrophy), 4D-725 (preclinical α1-antitrypsin deficiency lung disease), and 4D-310 (Phase 1 Fabry disease). Collectively, these programs address rare-disease indications that together represent a $30 billion addressable market for gene-therapy modalities.

Strategic collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure provide both development expertise and non-dilutive funding; the company reported a cash runway of approximately $150 million as of its latest 10-Q, supporting runway through at least 2026 under current burn rates.

For a deeper, data-driven look at FDMT’s valuation dynamics and scenario analysis, you might find the free tools on ValueRay useful for extending your own research.

FDMT Stock Overview

Market Cap in USD	587m
Sub-Industry	Biotechnology
IPO / Inception	2020-12-11
Return 12m vs S&P 500	17.4%
Analyst Rating	4.0 of 5

FDMT Dividends

Currently no dividends paid

FDMT Growth Ratios

CAGR 3y	-21.30%
CAGR/Max DD Calmar Ratio	-0.23
CAGR/Mean DD Pain Ratio	-0.42
Current Volume	775k
Average Volume	932.9k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-209.2m TTM) > 0 and > 6% of Revenue (6% = 7200 TTM)

FCFTA -0.44 (>2.0%) and ΔFCFTA -24.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 229.4k% (prev 2.83m%; Δ -2.60mpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.43 (>3.0%) and CFO -183.5m > Net Income -209.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (56.1m) change vs 12m ago 1.03% (target <= -2.0% for YES)

Gross Margin -80.7k% (prev -53.8k%; Δ -26.9kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.02% (prev 0.00%; Δ 0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -13.38 (EBITDA TTM -226.8m / Interest Expense TTM -16.9m) >= 6 (WARN >= 3)

Altman Z'' -18.39

(A) 0.65 = (Total Current Assets 312.4m - Total Current Liabilities 37.1m) / Total Assets 424.0m

(B) -1.74 = Retained Earnings (Balance) -735.7m / Total Assets 424.0m

warn (B) unusual magnitude: -1.74 — check mapping/units

(D) -13.36 = Book Value of Equity -735.0m / Total Liabilities 55.0m

Total Rating: -18.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.06

1. Piotroski 0.0pt = -5.0

2. FCF Yield -60.76% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.06 = 2.50

5. Debt/Ebitda 0.12 = 2.49

6. ROIC - WACC (= -50.40)% = -12.50

7. RoE -47.27% = -2.50

8. Rev. Trend -39.08% = -2.93

9. EPS Trend -39.89% = -1.99

What is the price of FDMT shares?

As of November 16, 2025, the stock is trading at USD 10.79 with a total of 775,036 shares traded.
Over the past week, the price has changed by +2.76%, over one month by +8.22%, over three months by +51.97% and over the past year by +34.54%.

Is 4D Molecular Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, 4D Molecular Therapeutics (NASDAQ:FDMT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 25.06 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FDMT is around 9.79 USD . This means that FDMT is currently overvalued and has a potential downside of -9.27%.

Is FDMT a buy, sell or hold?

4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.

Strong Buy: 5
Buy: 4
Hold: 2
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the FDMT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	33.1	206.9%
Analysts Target Price	33.1	206.9%
ValueRay Target Price	11.1	2.6%

FDMT Fundamental Data Overview November 15, 2025

Market Cap USD = 587.3m (587.3m USD * 1.0 USD.USD)
P/S = 4894.5713
P/B = 1.6986
Beta = 2.951
Revenue TTM = 120.0k USD
EBIT TTM = -226.1m USD
EBITDA TTM = -226.8m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.70m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 304.5m USD (587.3m + Debt 22.3m - CCE 305.1m)
Interest Coverage Ratio = -13.38 (Ebit TTM -226.1m / Interest Expense TTM -16.9m)
FCF Yield = -60.76% (FCF TTM -185.1m / Enterprise Value 304.5m)
FCF Margin = -154.2k% (FCF TTM -185.1m / Revenue TTM 120.0k)
Net Margin = -174.3k% (Net Income TTM -209.2m / Revenue TTM 120.0k)
Gross Margin = -9999 % ((Revenue TTM 120.0k - Cost of Revenue TTM 97.0m) / Revenue TTM)
Gross Margin QoQ = -9999 % (prev -9999 %)
Tobins Q-Ratio = 0.72 (Enterprise Value 304.5m / Total Assets 424.0m)
Interest Expense / Debt = 6.34% (Interest Expense 1.41m / Debt 22.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -178.6m (EBIT -226.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 312.4m / Total Current Liabilities 37.1m)
Debt / Equity = 0.06 (Debt 22.3m / totalStockholderEquity, last quarter 369.0m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -26.3m / EBITDA -226.8m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -185.1m)
Total Stockholder Equity = 442.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.34% (Net Income -209.2m / Total Assets 424.0m)
RoE = -47.27% (Net Income TTM -209.2m / Total Stockholder Equity 442.6m)
RoCE = -48.64% (EBIT -226.1m / Capital Employed (Equity 442.6m + L.T.Debt 22.3m))
RoIC = -40.36% (negative operating profit) (NOPAT -178.6m / Invested Capital 442.6m)
WACC = 10.05% (E(587.3m)/V(609.6m) * Re(10.24%) + D(22.3m)/V(609.6m) * Rd(6.34%) * (1-Tc(0.21)))
Discount Rate = 10.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.76%
Fair Price DCF = unknown (Cash Flow -185.1m)
EPS Correlation: -39.89 | EPS CAGR: -33.62% | SUE: 0.0 | # QB: 0
Revenue Correlation: -39.08 | Revenue CAGR: -61.55% | SUE: -0.08 | # QB: 0

Additional Sources for FDMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle